AstraZeneca PLC
NYSE:AZNDrug Manufacturers - General
-$3.04 today
- Market cap
- $277.23B
- Beta
- 0.21
- P/E (TTM)
- 25.7
- EPS (TTM)
- $6.75
- Dividend yield
- 1.80%
Volume 2.54M
Average 1.96M
AZN Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
AstraZeneca PLCNYSE: AZN
Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Free cash flow growth accelerates
Q3 FY2026 free cash flow of $3.99B rose 17.1% year over year, ahead of the -2.6% change in trailing-twelve-month free cash flow. Sequentially, it rose 86.9% from the prior quarter. Over 3 fiscal years it compounded at +6.2% a year.
Context
- Free cash flow amounted to 14.8% of revenue in FY2025, up 1.3 pp from a year earlier.
- Free cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +17.1% holds above the trailing-twelve-month pace of -2.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 8.67B USD
- Year-over-year change
- +19.2%
- 4-year CAGR
- +23.2%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.67B | +19.2% |
| FY2024 | 2024-12-31 | 7.28B | +10.8% |
| FY2023 | 2023-12-31 | 6.57B | -9.3% |
| FY2022 | 2022-12-31 | 7.24B | +92.3% |
| FY2021 | 2021-12-31 | 3.76B | — |
Free Cash Flow vs competitors
How AZN compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -2.6% is the 5th highest of 10, against a peer median of -4.1%.
- Free cash flow amounts to 15.0% of revenue for AZN, versus a peer median of 24.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 48.92B DKK | -20.6% | -23.3% | 14.8% | |
| LTM Sep 2026 | $20.59B USD | +7.9% | +4.7% | 20.7% | |
| LTM Jun 2026 | $20.05B USD | +40048.0% | +24.9% | 25.2% | |
| LTM Jun 2026 | $18.21B USD | -0.2% | -9.8% | 28.3% | |
| LTM Jun 2026 | $16.06B USD | +9.1% | -5.6% | 24.2% | |
| LTM Jun 2026 | $15.82B USD | -5.9% | +13.8% | 28.4% | |
| LTM Jun 2026 | $11.44B USD | -21.5% | +2.4% | 23.3% | |
| LTM Jun 2026 | $10.99B USD | -11.7% | -29.6% | 17.2% | |
| LTM Jun 2026 | $10.18B USD | -4.1% | -2.7% | 26.7% | |
| LTM Sep 2026 | $9.32B USD | -2.6% | +6.2% | 15.0% | |
| Peer median (excluding AZN) | — | -4.1% | -2.7% | 24.2% | |
Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (265M) | 2.5B | 6.9B | 8.69B | 10.23B |
| Depreciation & Amortization | 4.1B | 5.25B | 4.93B | 5.07B | 5.73B |
| Deferred Income Tax | (615M) | (619M) | 0 | 0 | 0 |
| Stock-Based Compensation | 615M | 619M | 579M | 0 | 0 |
| Change in Working Capital | 2.02B | 3.76B | 300M | (893M) | (1.16B) |
| Accounts Receivables | (961M) | (1.35B) | (1.43B) | (1.62B) | 0 |
| Inventory | 1.58B | 3.94B | (669M) | (131M) | 0 |
| Accounts Payables | 961M | 1.35B | 1.43B | 0 | 0 |
| Other Working Capital | 444M | (184M) | 969M | 862M | (1.16B) |
| Other Non-Cash Items | 105M | (1.7B) | (2.37B) | (1B) | (220.71M) |
| Operating Cash Flow | 5.96B | 9.81B | 10.35B | 11.86B | 14.58B |
| Capital Expenditures | (2.2B) | (2.57B) | (3.78B) | (4.59B) | (5.91B) |
| Acquisitions (Net) | (9.43B) | (1.06B) | (1.18B) | (3.93B) | (1.24B) |
| Purchases of Investments | (184M) | (159M) | (136M) | (96M) | (229M) |
| Sales of Investments | 105M | 42M | 129M | 108M | 131M |
| Other Investing Activities | 654M | 789M | (1.52B) | (2.14B) | (2.66B) |
| Investing Cash Flow | (11.06B) | (2.96B) | (4.06B) | (7.98B) | (6.81B) |
| Debt Repayment | 7.89B | (1.2B) | (965M) | 1.81B | (1.65B) |
| Common Stock Issued | 29M | 29M | 33M | (43M) | (481M) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (3.86B) | (4.36B) | (4.48B) | (4.63B) | (4.97B) |
| Other Financing Activities | (418M) | (1.29B) | (1.15B) | (1.13B) | (442M) |
| Financing Cash Flow | 3.65B | (6.82B) | (6.57B) | (4B) | (7.54B) |
| Effect of Forex Changes | (62M) | (80M) | (60M) | (93M) | 46M |
| Net Change in Cash | (1.51B) | (55M) | (346M) | (208M) | 269M |
| Free Cash Flow | 3.76B | 7.24B | 6.57B | 7.28B | 8.67B |
AstraZeneca PLC
NYSE:AZN
Intrinsic Alpha fair value
Locked
Current Price
$178.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.